National Council for Prescription Drug Programs indexing - billing unit
- Manufacturer
- National Council for Prescription Drug Programs
- Effective date
- 2012-07-24
- Label type
- Indexing - Billing Unit
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-05 02:19:26
Label at a glance#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 60793-853-10 | EA - Each | 60793-853 | 9bb14233-e040-46c0-8e59-fa018f46e62c | 1 | 2012-07-24 |
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 60793-853 | 60793-853-10 |
Source Document#
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021301-001 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-002 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-003 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-004 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-005 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-006 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-007 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-008 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-009 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-010 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 |
| N021301-011 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD, RS | 2001-05-25 |
| N021301-012 | LEVOXYL | LEVOTHYROXINE SODIUM | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2001-05-25 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N021301-001 | AB1 |
| N021301-001 | AB3 |
| N021301-002 | AB1 |
| N021301-002 | AB3 |
| N021301-003 | AB1 |
| N021301-003 | AB3 |
| N021301-004 | AB1 |
| N021301-004 | AB3 |
| N021301-005 | AB1 |
| N021301-005 | AB3 |
| N021301-006 | AB1 |
| N021301-006 | AB3 |
| N021301-007 | AB1 |
| N021301-007 | AB3 |
| N021301-008 | AB1 |
| N021301-008 | AB3 |
| N021301-009 | AB1 |
| N021301-009 | AB3 |
| N021301-010 | AB1 |
| N021301-010 | AB3 |
| N021301-011 | AB1 |
| N021301-011 | AB3 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021301-001 | LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-002 | LEVOXYL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-003 | LEVOXYL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-004 | LEVOXYL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-005 | LEVOXYL | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-006 | LEVOXYL | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-007 | LEVOXYL | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-008 | LEVOXYL | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-009 | LEVOXYL | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-010 | LEVOXYL | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-011 | LEVOXYL | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD, RS | 2001-05-25 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-012 | LEVOXYL | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2001-05-25 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021301-001 | LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-002 | LEVOXYL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-003 | LEVOXYL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-004 | LEVOXYL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-005 | LEVOXYL | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-006 | LEVOXYL | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-007 | LEVOXYL | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-008 | LEVOXYL | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-009 | LEVOXYL | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-010 | LEVOXYL | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-011 | LEVOXYL | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD, RS | 2001-05-25 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-012 | LEVOXYL | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2001-05-25 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-001 | LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-002 | LEVOXYL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-003 | LEVOXYL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-004 | LEVOXYL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-005 | LEVOXYL | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-006 | LEVOXYL | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-007 | LEVOXYL | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-008 | LEVOXYL | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-009 | LEVOXYL | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-010 | LEVOXYL | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-011 | LEVOXYL | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD, RS | 2001-05-25 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N021301-012 | LEVOXYL | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET / ORAL | RLD | 2001-05-25 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-001 | LEVOXYL | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-002 | LEVOXYL | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-003 | LEVOXYL | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021301-004 | LEVOXYL | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | TABLET / ORAL | AB1,AB3 | RLD | 2001-05-25 | 31067a03dcf5… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021301-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-001 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-002 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-002 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-003 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-003 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-004 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-004 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-005 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-005 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-006 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-006 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-007 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-007 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-008 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-008 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-009 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-009 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-010 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-010 | AB3 | 2 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-011 | AB1 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N021301-011 | AB3 | 2 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-001 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-001 | AB3 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-002 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-002 | AB3 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-003 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-003 | AB3 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-004 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-004 | AB3 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-005 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-005 | AB3 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-006 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-006 | AB3 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-007 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-007 | AB3 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-008 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-008 | AB3 | 2 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-009 | AB1 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N021301-009 | AB3 | 2 | caaa826d4ba7… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-001 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-001 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-001 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-002 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-002 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-002 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-003 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-003 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-003 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-004 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-004 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-004 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-005 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-005 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-005 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-006 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-006 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-006 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-007 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-007 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-007 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-008 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-008 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-008 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-009 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-009 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-009 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-010 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-010 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-010 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-011 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-011 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-011 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-012 | 6555581 | 2022-02-15 | 5c6f7cd8ea54… | |||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-012 | 7067148 | 2022-02-15 | Drug product | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021301-012 | 7101569 | 2023-10-02 | U-759 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N021301-001 | 6555581 | 2022-02-15 | 5d02ea3f76ae… | |||
| 2022-04-08 23:34 UTC | 2022-04 | N021301-001 | 7067148 | 2022-02-15 | Drug product | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N021301-001 | 7101569 | 2023-10-02 | U-759 | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N021301-002 | 6555581 | 2022-02-15 | 5d02ea3f76ae… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| LEVOXYL | LEVOTHYROXINE SODIUM | Pfizer Laboratories Div Pfizer Inc | 758588c3-c63e-491b-0aa2-4f50d80cb174 | 2020-12-15 | Boxed warning, Warnings, Adverse reactions | 60793-853-10 60793085310 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.